Oragenics, Inc. (NYSEAMERICAN:OGEN – Get Free Report) shares were down 1.1% during mid-day trading on Monday . The company traded as low as $0.7021 and last traded at $0.7070. Approximately 121,779 shares traded hands during mid-day trading, an increase of 45% from the average daily volume of 84,180 shares. The stock had previously closed at $0.7150.
Oragenics Price Performance
The stock’s fifty day moving average is $0.71 and its 200-day moving average is $0.89. The stock has a market cap of $2.91 million, a PE ratio of -0.06 and a beta of 1.21.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of OGEN. XTX Topco Ltd purchased a new position in Oragenics during the fourth quarter worth about $26,000. Bank of America Corp DE boosted its stake in Oragenics by 7,374.0% during the second quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock worth $59,000 after buying an additional 15,338 shares during the period. Sabby Management LLC purchased a new position in Oragenics during the third quarter worth about $77,000. Finally, DRW Securities LLC boosted its stake in Oragenics by 82.4% during the fourth quarter. DRW Securities LLC now owns 112,709 shares of the company’s stock worth $88,000 after buying an additional 50,900 shares during the period. Hedge funds and other institutional investors own 18.71% of the company’s stock.
About Oragenics
Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.
The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.
Featured Stories
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.
